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S U M M A R Y
B A C K G R O U N D : The global burden of disease due to
asthma and chronic obstructive pulmonary disease
(COPD) is substantial and particularly great in low-
and middle-income countries, including many African
countries. Management is affected by availability of
diagnostic tests and essential medicines. The study
aimed to explore the availability of spirometry services
and essential medicines for asthma and COPD in African
countries.
M E T H O D : Questionnaires were delivered to healthcare
workers at the annual meeting of the Pan African
Thoracic Society Methods in Epidemiology and Clinical
Research (PATS MECOR) and International Multidis-
ciplinary Programme to Address Lung Health and TB in
Africa (IMPALA). Data were analysed using simple
descriptive statistics.
R E S U LT S : A total of 37 questionnaires representing 13
African countries were returned. Spirometry availability
was 73.0%. The most common reasons for non-
availability were lack of knowledge of the utility of the
test. Within the study sample, 33.3% faced sporadic
availability due to maintenance issues. Essential medi-
cines availability ranged from 37.8% for inhaled
corticosteroid-long-acting beta-agonist inhalers to
100% for prednisolone 5 mg tablets, mainly due to
supply chain problems.
C O N C L U S I O N : There is varied availability of spirome-
try and WHO essential medicines for COPD and asthma
in African countries. Strategies are needed to improve
access to basic effective care for people with non-
communicable lung disease in Africa.
K E Y W O R D S : spirometry; asthma; COPD
NON-COMMUNICABLE RESPIRATORY diseases
(NCRDs) are a worldwide public health burden. The
prevalence of asthma and chronic obstructive
pulmonary disease (COPD) is increasing in most
developing countries.1 However, as resources are
inadequate, these diseases are neglected in many
African counties, and there is therefore an urgent
need to increase access to appropriate diagnostic and
treatment facilities.2,3 Morbidity and mortality rates
due to NCRDs are therefore high, adding to the
existing burden of infectious diseases.4 Spirometry
can be used objectively to diagnose airway disease,
and is therefore a valuable diagnostic aid. From the
small amount of literature on the availability of
spirometry and the challenges of its implementation
in Africa, it appears that availability is low.5
Similarly, the literature reports low availability
across African countries of the essential medicines
included in the WHO’s Model Essential Medicines
List (EML).5
Diagnostic tests and medicines are needed for
optimal management of patients with NCRDs and
the reduction of morbidity and mortality in Africa.
This study investigated the availability of spirometry
services and the WHO-recommended essential
medicines for asthma and COPD in African coun-
tries with the aim of defining the current situation
and describing the challenges for implementing
services, which could guide the development of




This was a cross-sectional survey to explore the
availability of spirometry and 15 different forms of
medications from the 20th edition of the WHO EML
that are essential for the management of chronic
respiratory diseases.6
Study population
Healthcare professionals who attended the PATS
MECOR and IMPALA Conference in June 2019
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were invited to complete the questionnaire during the
conference. The inclusion criteria were all healthcare
professionals who worked in an African healthcare
facility and had knowledge about the availability of
the diagnostic resources and medicines for asthma
and COPD in their facility. Participants were physi-
cians who worked in hospitals.
Data collection
A structured questionnaire comprising closed and
open-ended questions was developed. The question-
naire was piloted in the study. These were adminis-
tered during the Conference and were self-completed
by participants.
Analysis
Results were analysed using simple descriptive
statistics on Microsoft Excel (MicroSoft, Redmond,
WA, USA). Responses from open-answer questions
were grouped according to common responses.7
Some open-answer responses could not be grouped,
and these were quoted directly.
Approvals
Ethical approval was granted by the Liverpool School
of Tropical Medicine (LSTM) Research Ethics Com-
mittee, Liverpool, UK. PATS gave permission for data
collection at PATS MECOR. Participation was
voluntary and non-incentivised.
RESULTS
Thirty-seven questionnaires were completed by phy-
sicians representing 13 African countries. Nigerian
participants represented 30% of the total surveyed
(Figure).
Availability of spirometry in African countries
A total of 37 (73%) participants reported having a
spirometer at their facility, of whom 66.7% reported
uninterrupted availability. Among those facilities
with a spirometer, 77.8% of staff had training on
operating the spirometer and 70.4% on data inter-
pretation (Table 1). The most common reasons for
unavailability was the belief that spirometry was not
necessary or lack of training on how to use the
spirometer (Table 2).
Availability of WHO essential medicines for asthma
and COPD
The medicine with the greatest availability was
prednisolone 5 mg (100%), followed by salbutamol
100 mcg inhaler (94.6%). The least available
medicines were ipratropium bromide 20 mcg inhaler
(43.2%) and both doses of combination inhalers
(38.7%) (Table 3).
Payment modality for asthma and COPD medicines
For all medicines, the most common method of
payment was full out of pocket pay by patients.
Combination inhalers and ipratropium bromide were
reported to be the most likely to be paid out of
pocket. Salbutamol injections and prednisolone 25
mg tablets were most likely to be offered free of
Figure Pie chart showing countries represented by partici-
pants who completed the surveys. DRC¼ Democratic Republic
of Congo.






















Yes 73.0 66.7 59.3 77.8 70.4
No 27.0 33.3 29.6 11.1 18.5
Don’t know 0 0 11.1 11.1 11.1
Table 2 Reasons for why the spirometer was unavailable at
the healthcare facility (multiple responses possible)






No capacity in the facility 30.0
Not considered 50.0
No training for staff on how to
use the spirometer 50.0
No training for staff on how to
interpret the findings 40.0
No availability of disposals 30.0
Other 40.0
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charge to patients. Rates of subsidised and mixed
method payments were variable (Table 4).
Reasons for the unavailability of WHO essential
medicines in healthcare facilities
Reasons for the unavailability were explored if a
medicine was sometimes unavailable. Common
reasons across all medicines included ‘cost’, ‘not on
national EML’, ‘lack of training’, ‘supply chain
problems’, ‘procurement challenges’, ‘out of stock’
and ‘limited prescription’. The main reasons for
complete unavailability of all medicines were cost,
the belief that the drug in question was not required
and not being on the national EML; however, most
facilities provided alternative free-text explanations
(Table 5).
Other responses to explain drug unavailability
The most common alternative explanation for both
doses of beclometasone hydrofluoroalkane (HFA)
inhaler and combination inhalers being unavailable
were ‘supply problems’. Other reasons for budesonide
100 mcg and 200 mcg inhaler being unavailable
included ‘not cost-effective for pharmacies to store as
drugs expire’ and ‘can be purchased at pharmacy
shops by patients’. Prednisolone 25 mg tablets were
unavailable because it was ‘not on the market’. Other
reasons for salbutamol injection unavailability were
‘inhaled form is preferred’ and ‘not guideline-recom-
mended’. One other reason provided for the unavail-
ability of the salbutamol respiratory solution was ‘no
nebuliser equipment at the facility’. Reasons for
ipratropium bromide 20 mcg unavailability included
‘not currently available on the market, only nebuliser
forms available’ and ‘not covered by insurance’.
DISCUSSION
This study set out to evaluate the reported availability
of spirometry services and WHO essential medicines





















Beclometasone HFA inhaler 50 mcg 59.5 29.7 10.8 45.5
Beclometasone HFA inhaler 100 mcg 64.9 24.3 10.8 45.8
Budesonide inhaler 100 mcg 48.6 40.5 10.8 44.4
Budesonide inhaler 200 mcg 48.6 40.5 10.8 44.4
Combination inhaler budesonide þ formoterol 100/6 37.8 56.8 5.4 21.4
Combination inhaler budesonide þ formoterol 200/6 37.8 56.8 5.4 21.4
Adrenaline 1 mg in 1 ml ampoule 89.2 10.8 0 6.1
Hydrocortisone powder for injection 100 mg in vial 89.2 8.1 2.7 9.1
Prednisolone 5 mg 100.0 0 0 2.7
Prednisolone 25 mg 81.1 16.2 2.7 3.3
Salbutamol inhaler 100 mcg (dry powder) 94.6 5.4 0 22.9
Salbutamol injection 50 mcg/ml in 5 ml ampoule 48.6 43.2 8.1 22.2
Salbutamol metered-dose inhaler 100 mcg 83.8 10.8 5.4 19.4
Salbutamol respirator solution for nebulisers 5 mg/ml 78.4 18.9 2.7 34.5
COPD¼ chronic obstructive pulmonary disease; HFA¼ hydrofluoroalkane.
Table 4 Payment modalities for asthma and COPD medicines in African countries















Beclometasone HFA inhaler 50 mcg 18.2 22.7 40.9 18.2 0
Beclometasone HFA inhaler 100 mcg 20.8 25.0 37.5 16.7 0
Budesonide inhaler 100 mcg 16.7 16.7 50.0 17.0 0
Budesonide inhaler 200 mcg 16.7 22.2 44.4 16.7 0
Combination inhaler budesonide þ formoterol 100/6 7.1 14.4 64.3 14.3 0
Combination inhaler budesonide þ formoterol 200/6 7.1 14.4 64.3 14.3 0
Adrenaline 1 mg in 1 ml ampoule 27.3 15.2 45.5 12.1 0
Hydrocortisone powder for injection 100 mg in vial 27.3 18.2 42.4 12.1 0
Prednisolone 5 mg tablet 24.3 13.5 45.9 16.2 0
Prednisolone 25 mg 30.0 13.3 40.0 16.7 0
Salbutamol inhaler 100 mcg 17.1 17.1 48.6 14.3 2.9
Salbutamol injection 50 mcg/ml in 5 ml ampoule 33.3 0.0 55.6 11.1 0
Salbutamol metered-dose inhaler 100 mcg 16.1 12.9 58.1 12.9 0
Salbutamol respirator solution for nebulisers 5 mg/ml 24.1 6.9 51.7 17.2 0
Ipratropium bromide inhaler 20 mcg 6.3 12.5 68.8 12.5 0
COPD¼ chronic obstructive pulmonary disease; HFA¼ hydrofluoroalkane.
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at healthcare facilities where African participants
attending a conference work in the context of the
Global Action Plan for the Prevention and Control of
NCDs 2013–2020, which has a target of ‘80%
availability of the affordable basic technologies and
essential medicines, including generics, required to
treat major non-communicable diseases in both
public and private facilities’.8
The main finding from this study is that there is
modest availability of spirometry at health facilities
across Africa, with very limited availability of WHO
essential medicines, particularly inhaled steroids for
the management of asthma and COPD. Nearly three
quarters of participants had a spirometer at their
institution, while only four essential medicines
(adrenaline, hydrocortisone, salbutamol inhalers
and prednisolone) reached the WHO target for
availability.
The results are comparable to a 2009 survey of
PATS MECOR members that showed that 62% of
healthcare professionals used spirometry to diagnose
COPD.9 However, a systematic review found that
fewer than 30% of Ugandan and Nigerian healthcare
facilities had access to spirometry services.5 A survey
in Tanzania reported that only 1.9% of facilities in
the study had the appropriate equipment (including
spirometry) to manage NCRDs.10 Facilities in this
study were more likely to have training to perform
rather than interpret spirometry which risks misdi-
agnosis. A case study from Nigeria found that only
34% of respondents could perform full spirometry.11
About a third of facilities did not routinely calibrate
the spirometer, suggesting results may be poor quality
and incorrect. A previous review on dealing with
spirometry access in Africa identified low availability
of calibration equipment and technical support in
facilities as a challenge. Local equipment providers
are only available in a few African countries.2 A third
of the facilities with a spirometer had interrupted
access, highlighting issues of poor technical support
and capacity. Spirometry was never available in 27%
of facilities; this was generally because spirometry
was ‘not considered’ and ‘there was no training on
how to use the spirometer’. A review on the
challenges of accessing spirometry found that South
Africa was the only country providing formal
spirometry training. Inadequate training leads to a
lack of human resources and inaccurate results.2
Salbutamol inhalers were widely available but
steroid monotherapy inhalers and combination in-
halers had low availability. These results are similar
to a systematic review of studies from Uganda, Sudan,
Eritrea and Nigeria, which reported that salbutamol
inhalers were available in 70% of the facilities
included. In this review, combination inhalers were
only available in 45% of healthcare facilities in only
Uganda and Nigeria.5 Trends in the availability of
salbutamol, steroid and combination inhalers in this
survey are comparable to a study on the availability
of medicines for asthma in tertiary hospitals in
Nigeria.12 Beclometasone and budesonide were
mainly unavailable, despite being listed as essential
for the basic management of patients with these
diseases. Supply problems were reported and it is
noteworthy that budesonide inhalers were often not
on most national EMLs. The lack of availability of
steroid-containing inhalers is particularly worrying
given their central role in asthma management and
the recent Global Initiative for Asthma recommen-
dations for the use of inhaled corticosteroid/formo-
terol as needed in mild asthma.13
Cost was the main factor affecting availability of
combination inhalers. In a Nigerian study, the
unavailability of these medicines was also linked to
unaffordability.12 Ipratropium bromide had very low
availability. This is in line with reports from a



























Beclometasone HFA inhaler 50 mcg (n ¼ 11) 18.2 0 45.5 0 18.2 9.1 54.5
Beclometasone HFA inhaler 100 mcg (n ¼ 9) 22.2 0 55.6 0 22.2 11.1 55.6
Budesonide inhaler 100 mcg (n ¼ 15) 26.7 0 33.3 33.3 33.3 20.0 33.3
Budesonide inhaler 200 mcg (n ¼ 15) 26.7 0 33.3 6.7 33.3 13.3 40.0
Combination inhaler budesonide þ formoterol 100/6 (n ¼ 21) 38.1 0 28.6 0 28.6 19.0 38.0
Combination inhaler budesonide þ formoterol 200/6 (n ¼ 21) 38.1 0 28.6 0 28.6 19.0 38.0
Adrenaline 1 mg in 1 ml ampoule (n ¼ 4) 0 0 25.0 100.0 0 0 0
Hydrocortisone powder for injection 100 mg in vial (n ¼ 3) 25.0 0 0 50.0 25.0 0 0
Prednisolone 25 mg (n ¼ 6) 0 0 0 0 0 0 33.3
Salbutamol inhaler 100 mcg (n ¼ 2) 0 0 100.0 0 0 0 0
Salbutamol injection 50 mcg/ml in 5 ml ampoule (n ¼ 16) 12.5 0 25.0 12.5 37.5 12.5 37.5
Salbutamol metered-dose inhaler 100 mcg (n ¼ 4) 50.0 0 100.0 50.0 0 0 25
Salbutamol respirator solution for nebulisers 5 mg/ml (n ¼ 7) 14.3 14.3 57.1 0 28.6 28.6 14.3
Ipratropium bromide 20 mcg (n ¼ 18) 16.7 0 27.8 5.6 44.4 5.6 22.2
EML¼ Essential Medicines List; HFA¼ hydrofluoroalkane.
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systematic review of facilities in Eritrea, Nigeria,
Ghana, Uganda and Sudan—the highest availability
in healthcare facilities here was 14.3%.5 In addition
to being a COPD reliever, ipratropium bromide is
recommended for asthma management in case of life-
threatening exacerbations.14 Prednisolone had high
availability and is likely to be used widely due to low
cost. It should be noted that long-acting beta-agonists
as stand-alone inhalers are not on the WHO EML,
despite their importance in the management of
COPD.15 We suggest that this should be considered
for inclusion in the next WHO EML update. A
common reason for inconsistent medicines availabil-
ity was supply chain and stock issues which could
relate to problems with manufacturing, product
registration and distribution, among others. Absence
from the national EML appears to affect the ready
availability of medicines. A Ugandan survey noted
that aminophylline tablets, beclometasone inhalers
and salbutamol inhalers were the only essential
medicines for asthma and COPD on the Ugandan
national EML, impacting availability of other med-
icines.1 Full out of pocket pay was the main payment
modality for all medicines. This raises the issue of
affordability in NCRDs. A consequence of this may
be that pharmacies would stop stocking medicines
because of low demand. The Global Asthma Net-
work (GAN) reported that medications essential for
asthma treatment, especially steroid inhalers were
often inaccessible in resource-poor settings.16
Limitations of the study
Sampling PATS MECOR and IMPALA attendees may
have resulted in over-reporting of availability as most
were from urban, tertiary and often academic
hospitals. Over-reporting was noted by Kibridge et
al.1 and Mehrota, Oluwole and Gordon9 as a
potential problem with survey delivery in African
countries. Participants were mainly from Nigeria and
Uganda, whereas the other countries generally had
only one representative. Given the diversity in health
systems and economies, solutions based on results
may not be generalisable. Administering the surveys
during a conference increased the likelihood of recall
bias.
The majority of the questions were closed, which
limited the number of explanations that respondents
could provide to qualify their answers. Pre-defined
options may have led respondents towards particular
interpretations. For confidentiality purposes, names
of the healthcare facilities and positions of partici-
pants were not included, although these could have
been useful in interpreting responses. It is possible
that some results were duplicated because a small
number of attendees from Uganda and Nigeria may
have answered with regard to the same healthcare
facility. This did not become obvious in analysis,
emphasising the risk of recall bias. This work
provides a foundation for a larger-scale survey to
comprehensively evaluate the availability of the basic
essential medications for chronic respiratory disease
services, including healthcare staff training, access
and availability of diagnostics, and both pharmaco-
logical and non-pharmacological interventions for
diseases prevention and control.
Implications of study findings and recommendations
This study investigated continuous availability as
well as quality of spirometry, in contrast to the
previous survey administered at PATS MECOR
where the focus was on spirometry usage. Training
programmes to perform spirometry and interpreta-
tion of findings to ensure accurate results should be
made more available and accessible, with monitor-
ing of performance. PATS and Spirometry Training
Services Africa (STSA) are already running training
courses in several African countries.17,18 With
greater awareness, these courses can grow, and
funding can be raised to provide or subsidise the
equipment needed.
Across African countries, there is a strong need to
improve the availability of controller medications to
ensure optimal management and quality of life of
asthma and COPD patients. Combination inhalers
are costly and strategies are needed to improve
affordability. An update of the national EML in most
African countries is needed urgently to include the
most important medicines for treatment of these
diseases and possibly eliminate medications such as
oral salbutamol, which have a poor risk/benefit ratio.
CONCLUSION
The study found a variable, but generally, low
availability (below WHO targets) of diagnostic
spirometry and essential medicines for asthma and
COPD in 13 African countries, which was influenced
by several factors. We highlighted important gaps
that could be addressed to improve availability, which
countries will need to address individually. Further
research is required to evaluate the availability and
barriers to access to affordable quality assured
essential medicines and spirometers for NCRDs and
to path solutions to the barriers.
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R É S U M É
C O N T E X T E : Le poids mondial dû à l’asthme et aux
bronchopneumopathies chroniques obstructives
(BPCO) est substantiel et particulièrement important
dans les pays à revenu faible et moyen, incluant de
nombreux pays d’Afrique. Leur prise en charge est
affectée par la disponibilité des tests de diagnostic et des
médicaments essentiels. L’étude a voulu explorer la
disponibilité des services de spirométrie et de
médicaments essentiels de l’asthme et des BPCO dans
les pays d’Afrique.
M É T H O D E : Des questionnaires ont été distribués aux
travailleurs de santé dans le cadre de la réunion annuelle
de la Pan African Thoracic Society Methods in
Epidemiology and Clinical Research (PATS MECOR)
et de l’International Multidisciplinary Programme to
Address Lung Health and TB in Africa (IMPALA). Les
données ont été analysées par de simples statistiques
descriptives.
R É S U LT A T S : Ont été renvoyés 37 questionnaires
représentant 13 pays d’Afrique. La disponibilité de la
spirométrie a été de 73,0%. Les raisons les plus
fréquentes de non disponibilité ont été le manque de
connaissances relatives à l’utilité du test. Dans cet
échantillon, 33,3% étaient confrontés à une
indisponibilité sporadique due à des problèmes de
maintenance. La disponibilité des médicaments
essentiels est allée de 37,8% pour les inhalateurs de
corticostéroı̈des et de bêta-2 agoniste d’action prolongée
à 100% pour un comprimé de 5 mg de prednisolone,
l’indisponibilité étant surtout due à des problèmes de
chaı̂ne logistique.
C O N C L U S I O N : La disponibilité de la spirométrie est
variable ainsi que celle des médicaments essentiels de
l’OMS pour les BPCO et l’asthme dans les pays
d’Afrique. Des stratégies sont requises afin d’améliorer
l’accès à des soins de bases efficaces pour les patients
atteints de maladies pulmonaires non transmissibles en
Afrique.
R E S U M E N
M A R C O D E R E F E R E N C I A: La carga de morbilidad
mundial por asma y enfermedad pulmonar obstructiva
crónica (EPOC) es considerable, en especial en los paı́ses
de ingresos bajos y medianos, incluidos muchos paı́ses de
África. En su tratamiento influye la disponibilidad de
medios diagnósticos y medicamentos esenciales. En el
presente estudio se examinó la disponibilidad de
servicios de espirometrı́a y medicamentos esenciales
destinados al asma y la EPOC en paı́ses africanos.
M É T O D O: Se presentaron cuestionarios a los profesionales
de salud que asistieron a la conferencia anual MECOR-
IMPALA (Epidemiology and Clinical Research e
International Multidisciplinary Programme to Address
Lung Health and TB in Africa) de la Asociación Torácica
Panafricana. Los datos se analizaron mediante ı́ndices
estadı́sticos descriptivos sencillos.
R E S U LT A D O S: Se recibieron 37 repuestas a los
cuestionarios de 13 paı́ses africanos. La disponibilidad
de la espirometrı́a fue 73,0%. La razón más frecuente
para su ausencia fue el desconocimiento de la utilidad de
la técnica. En esta muestra, el 33,3% afrontaba una
disponibilidad esporádica debido a problemas de
mantenimiento. La disponibilidad de medicamentos
esenciales osciló entre 37,8% para los inhaladores de
la combinación corticoesteroides y b2-agonistas de
acción prolongada y 100% para los comprimidos de 5
mg de prednisolona, debido en primer lugar a problemas
en la cadena de suministros.
C O N C L U S I Ó N: La disponibilidad de la espirometrı́a y
los medicamentos esenciales de la OMS para la EPOC y
el asma es variable en los paı́ses africanos. Se precisan
estrategias que mejoren el acceso a una atención básica
eficaz de las personas con patologı́as respiratorias no
transmisibles en África.
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